Id: acc0867
Group: 2sens
Protein: beta-catenin
Gene Symbol: CTNNB1
Protein Id: P35222
Protein Name: CTNB1_HUMAN
PTM: phosphorylation
Site: Ser45
Site Sequence: HSGATTTAPSLSGKGNPEEED
Disease Category: Cancer
Disease: Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline: HuH-7
Disease Info:
Drug: Canagliflozin
Drug Info: "Canagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus by reducing renal glucose reabsorption and promoting urinary glucose excretion, with a recommended initial dose of 100 mg once daily, which may be increased to 300 mg based on clinical response and renal function."
Effect: modulate
Effect Info: "CANA promotes the proteasomal degradation of beta-catenin protein by increasing the phosphorylation of beta-catenin, thereby inhibiting the growth of hepatocellular carcinoma."
Note:
Score: 4.0
Pubmed(PMID): 31142735
Sentence Index:
Sentence:

Sequence & Structure:

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Withdrawn colorectal adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Recruiting cirrhosis of liver ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed chronic myelogenous leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Terminated neoplasm ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic carcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed Malignant Pancreatic Neoplasm ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CTNNB1-Ser45
Cancer Intensity
BRCA
COAD -0.184
HGSC -1.332
ccRCC
GBM 0.613
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.904

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 45 A Wilms tumor Phosphorylation 12239584
S 45 D Esophageal carcinoma Phosphorylation 31933784
S 45 D Head and neck squamous cell carcinoma Phosphorylation 21281788
S 45 D Non-small cell lung cancer Phosphorylation 35277183
S 45 D Colon cancer Phosphorylation 32041324
S 45 N Cutaneous melanoma Phosphorylation 11351304
S 45 N Nephroblastoma Phosphorylation 12239584
S 45 N Wilms tumor Phosphorylation 12239584
S 45 N Colorectal cancer Phosphorylation 11955436

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: